Related references
Note: Only part of the references are listed.Atezolizumab Treatment of Tumors with High Tumor Mutational Burden from MyPathway, a Multicenter, Open-Label, Phase IIa Multiple Basket Study
Claire F. Friedman et al.
CANCER DISCOVERY (2022)
High tumor mutation burden fails to predict immune checkpoint blockade response across all cancer types
D. J. McGrail et al.
ANNALS OF ONCOLOGY (2021)
Evaluation of TMB as a predictive biomarker in patients with solid cancers treated with anti-PD-1/CTLA-4 combination immunotherapy
Oliver Klein et al.
CANCER CELL (2021)
The Spectrum of Benefit from Checkpoint Blockade in Hypermutated Tumors
Benoit Rousseau et al.
NEW ENGLAND JOURNAL OF MEDICINE (2021)
Harmonization and Standardization of Panel-Based Tumor Mutational Burden Measurement: Real-World Results and Recommendations of the Quality in Pathology Study
Albrecht Stenzinger et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Immune Checkpoint Inhibitors for Lung Cancer Treatment: A Review
Keisuke Onoi et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study
Aurelien Marabelle et al.
LANCET ONCOLOGY (2020)
The interplay between cancer type, panel size and tumor mutational burden threshold in patient selection for cancer immunotherapy
Mahdi Golkaram et al.
PLOS COMPUTATIONAL BIOLOGY (2020)
Size matters: Dissecting key parameters for panel-based tumor mutational burden analysis
Ivo Buchhalter et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Local Determinants of the Mutational Landscape of the Human Genome
Abel Gonzalez-Perez et al.
CELL (2019)
Somatic mutation and clonal expansions in human tissues
Inigo Martincorena
GENOME MEDICINE (2019)
Optimizing panel-based tumor mutational burden (TMB) measurement
J. Budczies et al.
ANNALS OF ONCOLOGY (2019)
Scales and mechanisms of somatic mutation rate variation across the human genome
Fran Supek et al.
DNA REPAIR (2019)
Tumor mutational burden quantification from targeted gene panels: major advancements and challenges
Laura Fancello et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Measurement of tumor mutational burden (TMB) in routine molecular diagnostics: in silico and real-life analysis of three larger gene panels
Volker Endris et al.
INTERNATIONAL JOURNAL OF CANCER (2019)
Tumor mutational load predicts survival after immunotherapy across multiple cancer types
Robert M. Samstein et al.
NATURE GENETICS (2019)
Clinical Sequencing Defines the Genomic Landscape of Metastatic Colorectal Cancer
Rona Yaeger et al.
CANCER CELL (2018)
Characterization of cancer genomic heterogeneity by next-generation sequencing advances precision medicine in cancer treatment
Jialing Zhang et al.
PRECISION CLINICAL MEDICINE (2018)
Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients
Ahmet Zehir et al.
NATURE MEDICINE (2017)
Analysis of 100,000 human cancer genomes reveals the landscape of tumor mutational burden
Zachary R. Chalmers et al.
GENOME MEDICINE (2017)
Universal Patterns of Selection in Cancer and Somatic Tissues
Inigo Martincorena et al.
CELL (2017)
Identifying recurrent mutations in cancer reveals widespread lineage diversity and mutational specificity
Matthew T. Chang et al.
NATURE BIOTECHNOLOGY (2016)
Memorial Sloan Kettering-Integrated Mutation Profiling of Actionable Cancer Targets (MSK-IMPACT) A Hybridization Capture-Based Next-Generation Sequencing Clinical Assay for Solid Tumor Molecular Oncology
Donavan T. Cheng et al.
JOURNAL OF MOLECULAR DIAGNOSTICS (2015)